Search Results 2381-2390 of 16876 for Epilepsy (Partial Onset)

  1. Proofed 09-14-10dlh

    BUT CATAMENIAL. EPILEPSY IS SOMETHING UNIQUE TO. WOMEN. THAT'S WHERE … Katherine Noe, M.D.. Track 2 (1:01). "THE SEIZURES ARE VERY. STRONGLY INFLUENCED BY.

  2. Neurosurgery - Doctors - Mayo Clinic

    Van Gompel, M.D.. Neurosurgeon. Rochester, MN. Areas of focus: Epilepsy surgery, Acoustic neuroma surgery, Computer assisted brain surgery, Intraoperative ...

  3. Neurosurgery - Doctors - Mayo Clinic

    Van Gompel, M.D.. Neurosurgeon. Rochester, MN. Areas of focus: Epilepsy surgery, Acoustic neuroma surgery, Computer assisted brain surgery, Intraoperative ...

  4. Medical Research & Education - Mayo Clinic News Network

    ... epilepsy. Mayo Clinic is taking epilepsy research in a bold new direction, exploring treatment approaches to help patients living with the most severe and ...

  5. Medical Research & Education - Mayo Clinic News Network

    At Mayo Clinic, biomedical engineer Benjamin Brinkmann, Ph.D., is developing tools and technologies that help reveal brain patterns — making epileptic seizures ...

  6. A Study to Demonstrate that Acetazolamide is not Inferior to Diazepam for Patients who have Continuous Spike and Wave Brain Pattern in Sleep - Mayo Clinic

    The purpose of this study is to compare the effectiveness of the medications acetazolamide and diazepam for the treatment of patients who have continuous spike ...

  7. Neurology - Clinical trials

    ... onset cognitive impairment . Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset ...

  8. Vagus nerve stimulation - Doctors & Departments - Mayo Clinic

    Learn more about this procedure that may be used to treat epilepsy and other neurological conditions when other treatments haven't worked.

  9. Vagus nerve stimulation - Doctors & Departments - Mayo Clinic

    Learn more about this procedure that may be used to treat epilepsy and other neurological conditions when other treatments haven't worked.

  10. Phase IIB Study Of PHENOGENE-1A (Cromolyn) As An Adjuvant Therapy In Mild To Moderate ALS - Mayo Clinic

    Disease duration from ALS symptom onset of motor weakness ≤24 months. 6. ALSFRS-R total score ≥38 at screening visit. 7. ALSFRS-R Breathing subscore ...